Targeting the renin-angiotensin system in patients with renal disease.
Devonald
Mark A J
MA
Department of Medical Genetics, University of Cambridge, Cambridge, UK. majd2@medschl.cam.ac.uk
Karet
Fiona E
FE
D000804:Angiotensin II / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000075202:Contraindications; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007674:Kidney Diseases / Q000188:drug therapy*; D011507:Proteinuria / Q000188:drug therapy*; D012307:Risk Factors; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D014662:Vasoconstrictor Agents; D000804:Angiotensin II